Solvent recovery takes sting out of carbon tax

Grab the CFO and sharpen a pencil. The carbon dioxide tax is coming, and pharma manufacturers need to do something about it.

Drugmakers, of course, are among the biggest industrial consumers of solvents. So they stand to be among those hardest hit by the tax. But solvent recovery may help soften the blow, providing profit protection in the short run and getting processes on track for the inevitable lower emissions future.

To develop a CO2-tax action plan, figure out the impact of the tax on your operation, says Rockwell Automation in Sustainable Plant magazine. Cap-and-trade legislation is likely to yield a tax of $28 per ton.

Then compare an investment analysis of recovery versus incineration, with and without a carbon tax. Rockwell calculates a case where the carbon tax doubles the solvent recovery investment return while posing only moderate or lower-level risk.

- here's the case
- read more from Sustainable Plant (.pdf)

Relted Articles:
Recycle solvents for big emissions cut
AZ works to reduce energy, solvent use
Pfizer, Rowan pursue solvent recovery

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.